clinical trial · NCT07102368
A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany
Janssen-Cilag G.m.b.H·—·recruiting·n = 400
Inflammatory Bowel DiseaseColitis, UlcerativeCrohn's Disease
brief summary
The purpose of this study is to characterize participants with Crohn's Disease (CD) and Ulcerative Colitis (UC) treated with Guselkumab in a real-world setting, and to assess the clinical effectiveness (how well the treatment works) in the overall population and in different participant subgroups. Furthermore patient-reported outcomes like fatigue, health-related quality of life (HRQoL), sexuality, work productivity and activity as well as treatment satisfaction will be assessed.
started
Aug 18, 2025
primary completion
Jan 15, 2029
completion
Jan 15, 2029
last updated
Apr 13, 2026
official title
Generation of Real-world Evidence of Guselkumab in IBD Evaluating Effectiveness, Early Outcomes and Patient Relevant Aspects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol